Classifications

• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P30/00—Shaping or working of foodstuffs characterised by the process or apparatus
  • A23P30/20—Extruding
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
  • A61K9/5089—Processes
• • A—HUMAN NECESSITIES
  • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
  • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
  • A23P10/00—Shaping or working of foodstuffs characterised by the products
  • A23P10/20—Agglomerating; Granulating; Tabletting
  • A23P10/25—Agglomeration or granulation by extrusion or by pressing, e.g. through small holes, through sieves or between surfaces
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/01—Hydrocarbons
  • A61K31/015—Hydrocarbons carbocyclic
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/07—Retinol compounds, e.g. vitamin A
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/12—Ketones
  • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
  • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
  • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
  • A61K31/355—Tocopherols, e.g. vitamin E
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
  • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
  • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Definitions

• Granule comprising encapsulated active ingredients
• the present invention relates to water-dispersible powders for human consumption.
• Fat-soluble active ingredients as such cannot be dissolved in water. It is therefore common practice to encapsulate fat-soluble active ingredients.
• Water-dispersible microcapsules comprising fat-soluble micronutrients (e.g. fat-soluble vitamins) are commercially available at DSM Nutritional Products (Switzerland).
• Microcapsules are often poorly flowable, mostly due to their small particle size. To obtain a flowable powder, microcapsules are granulated.
• Granulation is a size enlargement process that is often done via wet granulation using a solvent (water or organic solvent) to initiate binding between solid particles (e.g. microcapsules). Dry granulation and melt granulation are known alternatives for wet granulation. Melt granulation operates via similar principles as wet granulation but typically uses a molten binder as a granulation fluid to establish liquid bridges between the particles to be granulated. When cooling to room temperature, the binder solidifies and forms bridges between individual powder particles to yield a solid end product with a granular structure.
• a solvent water or organic solvent
• melt granulation is done in a heated powder bed. This is a batch process: processing of subsequent batches must wait until the current is finished. This also applies to wet granulation done in conventional high-shear mixers.
• a drawback of wet granulation is the need of getting rid of the solvent at the end of the granulation process. In case of using water as solvent, a significant amount of energy is needed to evaporate water.
• a further drawback of wet granulation is the risk of hydrolysis of the active ingredient. In case of organic solvents, potentially harmful residues and/or negative environmental impacts are of concern.
• microcapsules and their content should remain essentially undamaged.
• the obtained granules should be flowable, storage stable and/or water-dispersible.
• the amount of fines (i.e. non-granulated residues) and/or the amount of surface oil should be low.
• the problems underlying the present invention are solved by continuous melt granulation of a mixture that comprises microcapsules.
• the continuous melt granulation process is preferably done in an extruder.
• a co-rotating twin-screw extruder continuously churns out free flowing granules; no die is needed at the end of the extruder.
• the mixture of the invention comprises at least one edible binder.
• the binder of the mixture is molten or at least softened.
• the microcapsules to be granulated comprise fat-soluble active ingredients. Some fat-soluble active ingredients are temperature sensitive. Prohibitively high temperature should be avoided when runningthe continuous melt granulation process of the invention. Thus, binders having a very high melting temperature or a very high glass transition (Tg) temperature are not preferred. In this context, "very high” can mean higher than 200°C or higher than 250°C.
• the mixture of invention further comprises at least one edible filler. In contrast to hot-melt extrusion, there is no need to melt the at least one edible filler during the continuous melt granulation process of the invention. The melting temperature of the at least one edible filler may therefore be significantly higher than the melting temperature of the at least one binder.
• a preferred mixture comprises a filler, a binder and microcapsules, wherein the mixture comprises from 0.1 weight-% to 55 weight-% of microcapsules, based on the total weight of the mixture, and wherein the mixture comprises from 5 weight-% to 15 weight-% binder, based on the total weight of the mixture, and wherein the weight ratio between filler and binder is from 4:1 to 9:1, and wherein the melting temperature of the binder is lowerthan the melting temperature of the filler, and wherein the melting temperature of the filler is from 151°C to 240°C.
• a method of manufacturing granules by continuous melt granulation comprises the step of feeding the mixture into an extruder, preferably into atwin-screw extruder.
• the granules of the invention comprise the mixture of the invention.
• the granules of the invention consist of the mixture of the invention.
• Extrusion granulation is often done with extruders. Extrusion granulation can be done with a solvent ("continuous wet granulation") or with heat (“continuous melt granulation”).
• the granules of the invention are obtainable by continuous melt granulation of a dry, edible mixture that comprises primary particles and at least two edible excipients. During continuous melt granulation, primary particles are agglomerated.
• the granule of the invention is preferably a unit formed of numerous particles. Primary particles of a granule are smaller than the granule.
• Both edible excipients are preferably water-soluble or water-dispersible.
• the melting temperature of a first edible excipient is low enough to be molten or at least be softened during continuous melt granulation. When molten or softened, the first edible excipient establishes bridges between the primary particles. Said bridges then solidify at room temperature. Therefore, the first edible excipient mostly acts as a binder. In the most preferred embodiment of the invention, the first edible excipient is sorbitol.
• the melting temperature of a second edible excipient is relatively high such that - typically - it does not fully melt or does not melt at all during continuous melt granulation.
• the second edible excipient mostly acts as a filler.
• the second edible excipient is inulin.
• the granule of the present invention may comprise one kind of primary particles only or preferably more than one kind of primary particles.
• the primary particles of the granule of the invention are preferably water-soluble or water-dispersible and comprise preferably at least one active ingredient.
• the primary particles are preferably water-soluble or water-dispersible microcapsules that encapsulate a fat-soluble active ingredient.
• Such microcapsules can be obtained by spray-drying of an emulsion comprising the lipophilic active ingredient and at least one emulsifier.
• the granules of the present invention are preferably water-soluble or water-dispersible. Compositions comprising or consisting of such granules are suitable for preparing a beverage.
• Fillers are excipients used to increase the volume of the granule of the invention. However, fillers can have further functions. Some fillers (e.g. dietary fibers) also have health benefits. The granule of the invention is meant for human consumption. Toxic fillers and non-edible fillers in general are therefore excluded.
• the granule of the invention is preferably water-soluble or water-dispersible. Fillers having a solubility of less than 1 g per 100 mL water or less than 0.5 g per 100 mL water or less than 0.1 g per 100 mL water are therefore not preferred.
• the melting temperature of the filler is higher than the melting temperature of the binder. There is no need to melt or soften the filler during continuous melt granulation.
• the melting temperature of the filler is preferably at least 150°C , more preferably at least 155°C and most preferably at least 160°C.
• the melting temperature of the filler is preferably from 151°C to 240° C, is more preferably from 180° C to 240° C and is most preferably from 180°C to 200°C.
• Preferred fillers are inulin, human milk oligosaccharides (HMOs) and mannitol.
• 2'-fucosyllactose (2’-FL) is the preferred HMO.
• a preferred filler is a mixture comprising 2’-fucosyllactose (2’-FL) and difucosyllactose (DFL).
• Granulated standard inulin is the preferred inulin.
• Standard inulin has a mean degree of polymerization (DP) from 10 to 20.
• Not preferred fillers are microcrystalline cellulose and pregelatinized starch.
• Binders are excipients used to hold the ingredients of a formulation together (i.e. are solid at room temperature). To do so, the binder is melted or softened during continuous melt granulation. Typically, the melting temperature of the binder is lower than the melting temperature of the filler and is often also lower than the melting temperature of any added active ingredient.
• the melting temperature of the binder is preferably less than 140°C, more preferably less than 130°C, even more preferably less than 120°C, and most preferably less than 110°C.
• the melting temperature of the binder is preferably from 50°C to 110°C, is more preferably from 60°C to 100°C and is most preferably from 70°C to 100°C.
• the granule of the invention is preferable water-soluble or water-dispersible. Binders having a solubility of less than 1 g per 100 mL water or less than 0.5 g per 100 mL water or less than 0.1 g per 100 mL water are therefore not preferred. Possible binders are inter alia ribose (such as D-ribose), polyethylene glycol, sorbitol and xylitol.
• the binder of the invention is preferably a polyol, is more preferably a sugar alcohol, is even more preferably sorbitol or ribose (e.g. D-ribose), and is most preferably sorbitol having a melting temperature of 98°C or less. Such sorbitol is commercially available at Roquette®.
• Microencapsulation is a protective technology for encapsulating solid or liquid active ingredients into microparticles with a diameter of e.g. 1-900 pm.
• the granule of the invention comprises multiple microcapsules.
• the size of the granule depends inter alia on the size of the microcapsules: relatively large microcapsules result in relatively large granules.
• microencapsulation lies in that the solid or liquid active ingredient is completely or almost completely coated and isolated from external environment. Microencapsulation may render fat-soluble active ingredients water-dispersible or water-soluble.
• Spray-drying is a suitable method for the microencapsulation of fat-soluble active ingredients. Prior to spray-drying, the fat-soluble active ingredient is mixed with at least one encapsulating agent. Typically, an emulsion is thereby provided. Gum Arabic is a commonly used encapsulating agent. Spray-drying is one of the most widely used microencapsulation techniques, since it provides rapid evaporation of water and maintains the low temperature in the particles. Spray-dried microcapsules comprising fat-soluble vitamins are commercially available at DSM Nutritional Products, Switzerland. Vitamins A, D, E, and K are exemplary fat-soluble vitamins. This includes derivatives thereof such as esters.
• the mixture of the invention is suitable for continuous melt granulation. It is a powderous mixture that can be fed into an apparatus that is suitable for continuous melt granulation (e.g. an extruder).
• the mixture of the invention comprises less than 10 weight-%, preferably less than 8 weight-%, more preferably less than 5 weight-% and most preferably less than 3 weight-% solvent, based on the total weight of the mixture. This applies not only, but in particular when the solvent is water.
• the preferred mixture of the invention comprises less than 10 weight-%, preferably less than 8 weight-%, more preferably less than 5 weight-% and most preferably less than 3 weight-% water, based on the total weight of the mixture.
• the mixture of the invention comprises or consists of a filler, a binder and microcapsules.
• the mixture of the invention comprises preferably from 40 weight-% to 95 weight-%, more preferably from 60 weight-% to 90 weight-% and most preferably from 70 weight-% to 80 weight-% of at least one filler, based on the total weight of the mixture.
• the mixture of the invention may comprise more than one filler.
• the invention may comprises one filler only.
• the filler is preferably a polysaccharide, is more preferably a dietary fiber, is even more preferably inulin and is most preferably granulated inulin powder.
• the mixture of the invention comprises less binder than filler.
• the weight ratio between the filler and the binder is preferably from 4:1 to 10:1, is more preferably from 5:1 to 10:1, is even more preferably from 6:1 to 9:1 and is most preferably from 7:1 to 8:1.
• the mixture of the invention comprises preferably from 5 weight-% to 15 weight-%, more preferably from 6 weight-% to 14 weight-% and most preferably from 8 weight-% to 13 weight-% of at least one binder, based on the total weight of the mixture.
• the mixture of the invention may comprise more than one binder. Preferably, however, the mixture of the invention comprises one binder only.
• the binder is preferably a polyol, is more preferably a sugar alcohol, is even more preferably sorbitol or ribose, and is most preferably sorbitol.
• the preferred ribose is D-ribose.
• the mixture of the invention comprises microcapsules.
• the mixture of the invention comprises preferably from 0.1 weight-% to 55 weight-%, more preferably from 1 weight-% to 40 weight-%, even more preferably from 1 weight-% to 30 weight-% and most preferably from 5 weight-% to 20 weight-% microcapsules, based on the total weight of the mixture.
• the herein described microcapsules encapsulate at least one fat-soluble active ingredient.
• Preferred fat-soluble active ingredients are fat-soluble micronutrients such as fat-soluble vitamins and pro-vitamins. Beta-carotene is an example of a fat-soluble pro-vitamin.
• the mixture of the invention comprises one kind of microcapsules only. In a preferred embodiment, however, the mixture of the invention comprises various kinds of microcapsules. In case of various kinds of microcapsules, the mixture of the invention comprises preferably at least two, more preferably at least three, even more preferably at least four and most preferably at least five fat-soluble active ingredients.
• the mixture of the invention comprises microcapsules comprising vitamin A, microcapsules comprising vitamin E, microcapsules comprising beta-carotene, microcapsules comprising vitamin D and/or microcapsules comprising vitamin K.
• the mixture of the invention comprises microcapsules comprising an ester of vitamin A (such as vitamin A acetate), microcapsules comprising an ester of vitamin E (such as vitamin E acetate), microcapsules comprising beta-carotene, microcapsules comprising vitamin D3 and/or microcapsules comprising vitamin K1.
• Preferred granules are obtainable by continuous melt granulation (i.e. without solvent) of the mixture of the invention, preferably using a twin-screw extruder.
• the granule of the invention comprises or consists of the mixture of the invention.
• the mixture of the invention comprises primary particles being preferably microcapsules. Upon continuous melt granulation, bridges are formed between the mixture's primary particles. Thus, the granule of the invention is larger than the size of its primary particles.
• Preferred granules of the present invention have a mass median particle size D50 (volume based) from 0.5 mm to 6 mm, preferably from 1 mm to 5 mm, more preferably from 1.5 mm to 4.5 mm and most preferably from 2 mm to 4 mm, measured using dynamic image analysis.
• Granules of the present invention may comprise more than 10, more than 100, more than 500 or even more than 1000 microcapsules. Each of the granule may comprise one kind of microcapsules only.
• the granule of the invention comprises various kinds of microcapsules.
• the granule of the invention comprises preferably at least two, more preferably at least three, even more preferably at least four and most preferably at least five fat-soluble active ingredients.
• the granule of the invention comprises microcapsules comprising vitamin A, microcapsules comprising vitamin E, microcapsules comprising beta-carotene, microcapsules comprising vitamin D, and/or microcapsules comprising vitamin K.
• the granule of the invention comprises microcapsules comprising an ester of vitamin A (such as vitamin A acetate), microcapsules comprising an ester of vitamin E (such as vitamin E acetate), microcapsules comprising beta-carotene, microcapsules comprising vitamin D3 and/or microcapsules comprising vitamin K1.
• an ester of vitamin A such as vitamin A acetate
• microcapsules comprising an ester of vitamin E such as vitamin E acetate
• microcapsules comprising beta-carotene microcapsules comprising vitamin D3 and/or microcapsules comprising vitamin K1.
• the granule of the invention comprises a filler, a binder and microcapsules, wherein the granule comprises from 0.1 weight-% to 55 weight-% of microcapsules, based on the total weight of the granule, and wherein the granule comprises from 5 weight-% to 15 weight-% binder, based on the total weight of the granule, and wherein the weight ratio between the filler and the binder is from 4:1 to 10:1, and wherein the melting temperature of the binder is lower than the melting temperature of the filler, and wherein the melting temperature of the filler is from 151°C to 240°C.
• the granule of the present invention is preferably water-soluble or water-dispersible. This can be achieved by selecting a binder that is water-soluble or water-dispersible, by selecting a filler that water-soluble or water-dispersible, and by selecting microcapsules that water-soluble or water-dispersible.
• the method of the invention is continuous melt granulation and is preferably continuous twin-screw melt granulation. Differences between batch melt granulation and continuous twin-screw melt granulation are listed in Table 1 of N. Kittikunakorn et aL, "Twin-screw melt granulation: Current progress and challenges", International Journal of Pharmaceutics, 588, (2020), 119670.
• the herein disclosed dry, powderous mixture is fed into an extruder that is suitable for continuous melt granulation. Volumetric powder feeders are thereby not preferred.
• the mixture of the invention is fed into the herein described extruder using a gravimetric powder feeder. Gravimetric powder feeders obtain a controlled and consistent feeding process, keeping changes in powder properties and process deviations over time into consideration.
• twin-screw extruder is preferably being used.
• twin-screw extruders with corotating screws are modular and can hence be configured in a variety of setups, resulting in various zones.
• the purpose of the first zone near the inlet of the extruder is transport. Transport zones are often referred to as conveying zones.
• One or more kneading zones can be present.
• the kneading zone is typically located between two conveying zones with preferably a shaping zone at the extruder outlet.
• each zone has different screw elements.
• the conveying zone has conveying elements that transport material towards the granulator outlet [cf. section 2.1 of N. Kittikunakorn et al., "Twin-screw melt granulation: Current progress and challenges", International Journal of Pharmaceutics, 588, (2020), 119670].
• the kneading zone has kneading elements with narrower or wider kneading disks.
• a typical shaping zone has at least one size control element that minimizes the amount of oversized granules. An exemplary size control element is shown in Figure 1(f) of J. Vercruysse et al.
• Size control elements are screw elements within the extruder.
• Hot-melt extrusion is different from the herein described continuous melt granulation.
• strands with e.g. a cylindric diameter are extruded through a die.
• the length of the strand is not limited (i.e. could be endless).
• strands obtained by hot- melt extrusion need to be cut into pieces.
• the obtained pellets are not granules formed of distinguishable primary particles.
• the cutting step can be done at any time after extrusion, including directly at the die of the extruder. Dies with an integrated knife are commercially available.
• the screw configuration of a twin-screw extruder is typically selected such that the extruder has at least one kneading zone.
• the at least one kneading zone is preferably closer to the powder inlet of the extruder than to the end of the extruder.
• Kneading zones have kneading elements. Said kneading elements are preferably kneading disks as disclosed in US 2005/0041521. Kneading disks may be congruent or non-congruent and are preferably positioned at a stagger angle from 30° to 90°. A stagger angle of approx.
• stagger angle refers to the angle of crest misalignment that make two directly successive kneading disks, as explained in paragraph [0007] of US 2005/0041521.
• stagger angle 30° means that there are successive kneading disks which make an angle of crest misalignment of 30°. There may be more than two successive kneading disks in a kneading zone of an extruder.
• Figure 2 of US 2005/0041521 is a lateral view of a kneading zone with five successive kneading disks, wherein the kneading disks are positioned at a predetermined stagger angle.
• the extruder has several zones which can be heated up or cooled down individually.
• temperature zones closer to the powder inlet of the extruder are typically heated.
• choosing a suitable temperature it must be taken into consideration that the material in the extruder may be moving rather quickly such that the contact of the material with the heating element is rather short. In some cases, it may therefore be advisable to set the temperature of some zones of the extruder to a temperature above the melting temperature of the mixture's binder.
• the conveying zone and/or the kneading zone of the extruder are heated, preferably to a temperature from 90°C to 200°C, more preferably to a temperature from 100°C to 180°C and most preferably to a temperature from 110°C to 170°C.
• Hot granules may still be relatively soft and sticky. As a consequence, hot granules may form a lump. This is to be avoided. It is therefore preferred to cool the material in the extruder before it is churned out by the extruder. In a preferred embodiment of the invention, at least one of the zones after the kneading is cooled down to a temperature of less than 60° C, preferably less than 40° C and most preferably less than 26° C. Examples
• a powderous premix comprising a mixture of microcapsules was provided.
• Each kind of microcapsule comprised a fat-soluble vitamin or a precursor of a fat-soluble vitamin. All microcapsules were obtained from DSM Nutritional Products (Switzerland).
• the premix provided in example 1 comprised vitamin A acetate, beta-carotene, vitamin D3, vitamin E acetate and vitamin K.
• Example 2 a dry mixture comprising 47.13 weight-% inulin Orafti®GR (filler), 10 weight-% D-ribose (binder) and 42.87 weight-% premix of example 1, based on the total weight of the dry mixture, was provided.
• the weight ratio between filler and binder was 4.7:1.
• Orafti®GR is granulated inulin powder (average degree of polymerization > 10), available at Beneo, Mannheim, Germany). Its melting point has been determined in the range 190-195°C.
• the dry mixture of example 2 was then fed into a ThermoFisher® Eurolab® extruder, using a gravimetric loss-in-weight feeder at the powder inlet.
• the extruder had a length-to-diameter (L/D) ratio of 25/1 and a screw diameter of 16 mm.
• the corotating screws of the extruder were fully modular and could hence be configured in a variety of setups.
• the extruder was segmented in several zones which can be heated up or cooled down individually.
• the extruder had one kneading zone with three wide kneading disks that were positioned at a stagger angle of 60° (i.e. the angle of crest misalignment between any two directly successive kneading disks made 60° C).
• example 3 the process of example 2 was repeated. However, instead of D-ribose, sorbitol was used as binder. Pre-experiments showed that the lowest possible processing temperature of sorbitol, still generating granules with desirable quality attributes, was approx. 85°C (i.e. slightly higher than D-ribose).
• Example 4 (more filler; effect of dilution)
• example 4 the process of example 3 was repeated. However, less premix and more filler was used.
• the dry mixture of example 4 comprised 72.85 weight-% inulin Orafti® GR (filler), 10 weight-% sorbitol (binder) and 17.15 weight-% premix of example 1, based on the total weight of the dry mixture.
• the weight ratio between filler and binder was approx. 7.3:1.
• Example 4 five extrusion experiments were run. Temperature schemes of example 2 were applied. A screw configuration consisting of a single kneading zone with 3 kneading disks positioned at a stagger angle of 30° was used.
• Example 4 shows the benefit of diluting the microcapsules with filler: when reducing the concentration of microcapsules in the mixture that were fed into the extruder, less stress was exerted on the microcapsules.
• Example 4 also shows the benefit of using a stagger angle of less than 60°.
• non-granulated inulin is also not preferred.
• Inulin HSI® a high soluble inulin powder
• microcrystalline cellulose melting point approx. 250°C
• Avicel PH200 is dispersible in water but is not water-soluble.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Food Science & Technology (AREA)
• Polymers & Plastics (AREA)
• Manufacturing & Machinery (AREA)
• Medicinal Preparation (AREA)
• General Preparation And Processing Of Foods (AREA)
• Coloring Foods And Improving Nutritive Qualities (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=78676359

Family Applications (1)

Country Status (5)

Citations (7)

Family Cites Families (6)

• 2022
  • 2022-11-16 EP EP22818325.7A patent/EP4432861B1/en active Active
  • 2022-11-16 JP JP2024527377A patent/JP2024541321A/ja active Pending
  • 2022-11-16 CN CN202280075701.4A patent/CN118234387A/zh active Pending
  • 2022-11-16 WO PCT/EP2022/082128 patent/WO2023088962A1/en not_active Ceased
  • 2022-11-16 US US18/709,316 patent/US20240423925A1/en active Pending

Patent Citations (7)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events